12 Month Price Forecast For EPRX
Distance to EPRX Price Forecasts
EPRX Price Momentum
๐ค Considering Eupraxia (EPRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 9:50 PM UTC
EPRX Analyst Ratings & Price Targets
Comprehensive analyst forecasts are currently unavailable for EPRX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EPRX Analyst Consensus
EPRX Price Target Range
Latest EPRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EPRX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 14, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
Stocks Similar to Eupraxia Pharmaceuticals Inc.
The following stocks are similar to Eupraxia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eupraxia Pharmaceuticals Inc. (EPRX) Financial Data
Eupraxia Pharmaceuticals Inc. has a market capitalization of $114.52M with a P/E ratio of -2.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -314.4%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Eupraxia Pharmaceuticals Inc. (EPRX) Company Overview
About Eupraxia Pharmaceuticals Inc.
Develops biotechnology solutions for various medical conditions.
Eupraxia Pharmaceuticals Inc. operates as a clinical stage biotechnology company, focusing on the discovery and development of innovative therapies. The company generates revenue through the advancement of its product candidates, which target unmet medical needs in areas such as pain relief from knee osteoarthritis and eosinophilic esophagitis, with potential future earnings from successful commercialization and partnerships.
The company is currently conducting Phase III and Phase II clinical trials for its lead products, demonstrating a commitment to addressing significant health challenges. Established in 2011 and based in Victoria, Canada, Eupraxia Pharmaceuticals was formerly known as Plaza Capital Partners Inc. and rebranded in 2012.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
29
CEO
Dr. James A. Helliwell FRCPC, M.D.
Country
Canada
IPO Year
2024
Website
www.eupraxiapharma.comEupraxia Pharmaceuticals Inc. (EPRX) Latest News & Analysis
Eupraxia Pharmaceuticals announced promising Phase 2a trial results for DiffuSphereโข, offering effective, long-lasting drug delivery for conditions like eosinophilic esophagitis and osteoarthritis.
Eupraxia's DiffuSphereโข shows promise in delivering drugs effectively and safely, potentially expanding treatment options across multiple diseases, which could drive investor interest and stock value.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) CEO will present on Eosinophilic Esophagitis, a growing disorder affecting over 450,000 U.S. patients, at a public webinar.
Eupraxia Pharmaceuticals is addressing a growing health issue, EoE, with its innovative drug delivery technology, potentially positioning the company for significant market opportunities and investor interest.
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
2 months agoEupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) will present a poster at the ACR Convergence 2024 Annual Meeting from November 14-19, showcasing its DiffuSphereโข drug delivery technology.
Eupraxia's presentation at a major medical conference highlights its innovative drug delivery technology, potentially attracting investor interest and impacting stock performance.
One patient in Cohort 5 achieved complete histological remission at 12 weeks, with all six evaluable patients in cohorts four and five showing symptom score reductions.
The news indicates positive clinical trial results, suggesting potential efficacy of a treatment, which may boost investor confidence and impact stock prices of the involved company.
Eupraxia Pharmaceuticals (NASDAQ: EPRX, TSX: EPRX) reported its Q3 2024 financial results, focusing on its DiffuSphereโข technology for drug delivery in unmet medical needs.
Eupraxia's Q3 financial results indicate its performance and progress in drug delivery technology, which could influence stock valuation and investor sentiment in the biotech sector.
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
3 months agoEupraxia Pharmaceuticals completed a non-brokered private placement, raising C$44.5 million by issuing 8.9 million Series 1 Preferred shares at C$5.00 each, to fund clinical trials and research.
Eupraxia's successful C$44.5 million private placement indicates strong investor confidence and provides crucial funding for clinical trials, potentially enhancing its market position and future growth.
Frequently Asked Questions About EPRX Stock
What is Eupraxia Pharmaceuticals Inc.'s (EPRX) stock forecast for 2025?
Analyst forecasts for Eupraxia Pharmaceuticals Inc. (EPRX) are not currently available. The stock is trading at $3.24.
Is EPRX stock a good investment in 2025?
Analyst ratings for EPRX are not currently available. The stock is currently trading at $3.24. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for EPRX stock?
Price predictions from Wall Street analysts for EPRX are not currently available. The stock is trading at $3.24.
What is Eupraxia Pharmaceuticals Inc.'s business model?
Eupraxia Pharmaceuticals Inc. operates as a clinical stage biotechnology company, focusing on the discovery and development of innovative therapies. The company generates revenue through the advancement of its product candidates, which target unmet medical needs in areas such as pain relief from knee osteoarthritis and eosinophilic esophagitis, with potential future earnings from successful commercialization and partnerships.
What is the highest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
Price targets from Wall Street analysts for EPRX are not currently available. The stock is trading at $3.24.
What is the lowest forecasted price for EPRX Eupraxia Pharmaceuticals Inc.?
Price targets from Wall Street analysts for EPRX are not currently available. The stock is trading at $3.24.
What is the overall EPRX consensus from analysts for Eupraxia Pharmaceuticals Inc.?
Analyst ratings for EPRX are not currently available. The stock is trading at $3.24.
How accurate are EPRX stock price projections?
Stock price projections, including those for Eupraxia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.